To view this email as a web page, click here.

Can Crowdsourcing Lead to Artificial Intelligence Tools for Radiation Oncologists?

A worldwide crowd innovation contest incentivized international programmers to create automated AI algorithms for an area of radiation oncology.

Dr. Oratz on PARP Inhibitors to Treat Patients With Breast Cancer

Cancer Network spoke with Ruth Oratz, MD, a medical oncologist at NYU Langone Perlmutter Cancer Center in New York City, about the use of PARP inhibitors for breast cancer.

IN CASE YOU MISSED IT

Practice-Changing Results Seen in Phase III Relapsed/Refractory AML Trial

Results of the phase III ADMIRAL trial, which tested the FLT3 inhibitor gilteritinib in patients with relapsed/refractory acute myeloid leukemia, were presented at the AACR Annual Meeting.

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.